Meag Munich Ergo Kapitalanlagegesellschaft MBH Has $16.62 Million Stake in Gilead Sciences, Inc. (GILD)
Meag Munich Ergo Kapitalanlagegesellschaft MBH lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 29.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 235,052 shares of the biopharmaceutical company’s stock after selling 95,870 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in Gilead Sciences were worth $16,624,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the company. Rockland Trust Co. raised its position in shares of Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock valued at $12,106,000 after buying an additional 25,551 shares during the period. Linscomb & Williams Inc. raised its position in shares of Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 154 shares during the period. Berkshire Asset Management LLC PA purchased a new position in shares of Gilead Sciences during the first quarter valued at $270,000. Sigma Planning Corp raised its position in shares of Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock valued at $2,728,000 after buying an additional 2,889 shares during the period. Finally, Hollencrest Securities LLC raised its position in shares of Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock valued at $525,000 after buying an additional 4,210 shares during the period. Institutional investors and hedge funds own 74.02% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up 1.46% during trading on Tuesday, reaching $73.66. The company’s stock had a trading volume of 2,009,648 shares. The company’s 50-day moving average price is $72.66 and its 200 day moving average price is $68.77. The stock has a market capitalization of $96.19 billion, a price-to-earnings ratio of 8.00 and a beta of 1.21. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.10.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.08 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post $8.74 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s payout ratio is currently 22.58%.
TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/22/meag-munich-ergo-kapitalanlagegesellschaft-mbh-has-16-62-million-stake-in-gilead-sciences-inc-gild.html.
GILD has been the topic of several research reports. William Blair reaffirmed an “outperform” rating on shares of Gilead Sciences in a research report on Friday, June 16th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $79.00 target price on shares of Gilead Sciences in a research report on Friday, May 5th. Leerink Swann reaffirmed a “hold” rating and issued a $74.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 25th. Finally, Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 target price on the stock in a research report on Friday, July 28th. Eleven equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $80.64.
In related news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total value of $1,138,200.00. Following the sale, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last three months, insiders sold 206,666 shares of company stock worth $15,223,184. 1.30% of the stock is currently owned by insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.